Kazuhiro Nishimiya

Immunogenicity of Therapeutic Protein Products: Current Considerations for Anti-Drug Antibody Assay in Japan

Akiko Ishii‐Watabe, Hiroko Shibata, Kazuko Nishimura et al. · Bioanalysis · 2017 · 33 citations · Full text

Life Sciences, Immunology, Pharmaceutics +17

1,25-Dihydroxyvitamin D3 and 22-oxa-1,25-dihydroxyvitamin D3 in vivo nuclear receptor binding in developing bone during endochondral and intramembranous ossification

Walter E. Stumpf, Nobuo Koike, Naohiko Hayakawa et al. · Histochemistry and Cell Biology · 1994 · 16 citations

Medicine, Endocrinology, Bone Metabolism +16

Distribution of 1,25-dihydroxyvitamin D3[22-oxa] in vivo receptor binding in adult and developing skin

Walter E. Stumpf, Nobuo Koike, Naohiko Hayakawa et al. · Archives of Dermatological Research · 1995 · 15 citations

Medicine, Biochemistry, Dermatology +10

In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [3H]1,25-dihydroxy-22-oxavitamin D3 compared with [3H]1,25-dihydroxyvitamin D3, determined by micro-autoradiography

Nobuo Koike, Naohiko Hayakawa, Kazuo Tokuda et al. · Nephrology Dialysis Transplantation · 2002 · 12 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC–MS/MS, and its application in a clinical trial

Tomonori Kamei, Takahide Uchimura, Kazuhiro Nishimiya et al. · Journal of Chromatography B · 2011 · 11 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +15